Browse Studies — Arctuva

Phase 1

Phase I Study of Combined Deceased Donor Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment

This is a single arm phase 1 non randomized dose finding study for safety, feasibility and efficacy of deceased donor vertebral body (VB) marrow cell infusion …

Immune Tolerance

Estimated

~$10 – $6,250

Stanford UniversityNCT04571203

Phase 1

Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-cell Transfusion to Withdraw Immunosuppressive Drugs From Recipients of a Previous HLA Matched Living Donor Kidney Transplantation .

The study will determine whether patients with functioning Human Leukocyte Antigen (HLA) matched kidney transplants for at least one year and who want to disco…

Immune Tolerance

Estimated

~$10 – $7,500

Stephan BusqueNCT03591302

Phase 1

A Phase I Feasibility Study of HSPC Infusion Following Total Lymphoid Irradiation and Anti-thymocyte Globulin in Patients With a Pre-existing, Well-functioning HLA-matched Living-donor Liver Transplant to Induce Immune Tolerance.

This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use o…

Liver TransplantationImmune ToleranceImmune Tolerance/Drug Effects+6 more

Estimated

~$10 – $6,250

University of California, Los AngelesNCT07269041